The government commission for more sustainable development of the Russian economy, according to its meeting's minutes No. 13-КЗ of June 19, 2020, included the Medsintez plant into the list of the Russian Federation's systemic enterprises whose products or services are vital for sustaining a territory, functioning of an industry and a region's social and economic system.
During the pandemic and the unstable global financial and economic situation, the Government of Russia has been hard at work on updating the list of the country's systemic enterprises, which are socially significant and important for the whole state. Being enrolled into the list means higher level of social responsibility of such a company. According to Andrei Belousov's, the First Deputy Prime Minister of the Russian Federation, decision, the enrolled enterprises can, if necessary, receive support: to qualify for soft loans, get government guarantees necessary to restructure existing or receiving new loans and bond loans, delay tax payments and even receive direct subsidies. In addition, Mikhail Mishustin, Russian Prime Minister, signed a decree making relevant ministries continuously monitor the financial and economic state of Russia's systemic enterprises.
The Medsintez plant is a single pharmaceutical complex that manufactures substances, liquid and solid dosage forms of drugs, in compliance with GMP requirements. The company manufactures infusion solutions, finished dosage forms of genetically engineered human insulin (by 2021, the full cycle and the production of analog insulin is expected), Primapur® (a recombinant follicle-stimulating human hormone and Russia's first drug for infertility) and Triazavirin® (the innovative broad-spectrum antiviral drug recommended as COVID-19 treatment and prevention). In April 2020, the plant launched a mask production line within a short time. Today, the enterprise employs more than 300 highly skilled specialists.
Medsintez is one of Sverdlovsk region's core healthcare enterprises. In 2007, the plant became the first pharmaceutical company in Russia to be awarded the Russian Government Prize in the field of quality by President Vladimir Putin. Today, Medintez plant's products are in demand throughout the country. Its production capacity is able to meet 100% of the region's and country's demand in high-quality and affordable medicines. High standards of products manufactured, the creation and implementation of new technologies, incessant scientific research and focus on import substitution make the Medsintez plant a systemic enterprise in this country. In June 2020, the plant joined the Bioorganica Consortium of the NTI Center of IBCh RAS, which creates advanced products and technologies in order to boost the efficiency of the country's economy and increase the duration and quality of life of the population. The Medsintez plant is also the base organization for regional associations, such as the Ural Biomedical Cluster or the Association of Medical and Pharmaceutical Manufacturers of the Sverdlovsk Region. The plant contributed a lot to the accumulation of the region's scientific, innovative, industrial, commercial and human potential within these organizations.